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rs8099917
rs12979860
rs8103142The present study is the first investigation of the association between single nucleotide polymorphisms
(SNPs – rs8099917, rs12979860 and rs8103142) of the IL28B gene and the development of human
T-lymphotropic virus (HTLV)-associated arthropathy (HAA). Individuals with HAA exhibited low
interleukin (IL) 6 (p < 0.05) and high IL-10 (p < 0.05) levels compared with asymptomatic patients.
TNF-a/CD4+ T cell count, TNF-a/CD8+ T cell count and IFN-c/proviral load positively correlated in asymp-
tomatic patients. The allelic and genotypic frequencies did not differ between patients with HAA and
asymptomatic patients. Seven haplotypes were detected in the investigated population, with haplotype
CCT (p < 0.05) being the most frequent among the HTLV-infected individuals, while haplotype TTG
(p < 0.05) was detected in the group with HAA only. Compared with asymptomatic patients, individuals
with HAA and genotype TT (rs8099917) exhibited larger numbers of CD8+ T cells (p < 0.05) and higher
proviral load levels (p < 0.05). Those patients with HAA and genotypes CC (rs12979860) and TT
(rs8103142) exhibited high TNF-b (p < 0.05) and IFN-c (p < 0.05) levels. Those patients with HAA and
genotype CT/TT (rs12979860) exhibited high IL-10 levels (p < 0.05). These results suggest that haplotypes
CCT and TTG might be associated with susceptibility to HTLV infection and progression to HAA, respec-
tively. Genotype TT (rs8099917) might be a risk factor for elevation of the proviral load and CD8+ T cell
count. In addition, genotypes CC (rs12979860) and TT (rs8103142) seem to be associated with increased
TNF-b and IFN-c levels.
 2015 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human T-lymphotropic virus 1 (HTLV-1) and Human
T-lymphotropic virus 2 (HTLV-2) are members of family Retroviri-
dae, genus Deltaretrovirus [1]. These viruses exhibit similar biolog-
ical properties, tropism for T lymphocytes [2–5] and a worldwide
geographic distribution [6].The main diseases associated with HTLV-1 are adult T-cell
leukemia/lymphoma (ATLL) [7] and HTLV-1-associated myelopa-
thy/tropical spastic paraparesis (HAM/TSP) [8]. Several rheumatic
diseases have also been associated with HTLV-1 infection, includ-
ing rheumatoid arthritis [9], Sjögren’s syndrome [10] and systemic
lupus erythematosus [11]. Those clinical conditions seem to result
from interactions between the virus and certain host immune
response factors, thus causing an imbalance in the immunomodu-
lation of cell proliferation and inflammation [12].
Studies have shown that HTLV-1 exhibits tropism for synovial
CD68+ cells, which, upon becoming infected with the virus, pro-
duce tumor necrosis factor alpha (TNF-a), which stimulates cell
proliferation and the destruction of articular cartilage through
erosion [13]. Aono et al. [14] showed that extracellular HTLV-1
80 K.S.G. de Sá et al. / Cytokine 77 (2016) 79–87Tax protein can activate transcription factors such as the nuclear
factor kappa-light-chain-enhancer of activated B cells (Nf-jB)
and activator protein 1 (AP-1) in human synovial cells. The prod-
ucts of the activation of such factors might play a significant role
in the pathogenesis of HTLV-associated arthropathy (HAA) [14].
HTLV-1 has been described as being able to infect a wide variety
of cell types both in vitro and in vivo. Nevertheless, CD4+ and, to a
lesser degree, CD8+ T cells are considered to be the main targets of
HTLV-1 [15,16]. Although infection is latent in most T cells and
thus undetectable by the host immune system, productive infec-
tion by HTLV activates lymphocytes, whose response is mediated
by multiple cell and humoral immune response mechanisms [17].
Cytokines play a central role in regulating the immune response
against HTLV-1 [18] and represent the main defensive strategy
presented by the host immune system to control viral replication,
and the proliferation of infected cells is mediated by CD8+ T lym-
phocytes [19,20].
Infection with HTLV-1 induces the activation and intense prolif-
eration of infected T cells. This phenomenon is mainly associated
with the function of the virus Tax gene, which is able to transacti-
vate the interleukin-2 (IL-2) and IL-2 receptor genes [21]. Indis-
criminate cell proliferation might result in the expansion of
autoreactive T cells and considerable secretion of proinflammatory
cytokines such as TNF-a. These changes might be associated with
skin and neurologic injury [22]. Thus, studying the role of pro-
and anti-inflammatory cytokines and the polymorphisms of the
corresponding genes might be highly relevant for elucidating the
pathophysiology of diseases associated with HTLV-1.
Interferon lambda 3 (INF-k3), also known as interleukin-28B
(IL-28B), is among the cytokines with a major role in immunomod-
ulation and in the antiviral response [23–25] and has demon-
strated the potential to increase CD8+ T cell counts in the
peripheral blood of monkeys [26]. Three single nucleotide poly-
morphisms (SNPs) have been described for this gene:
rs12979860 (C > T) and rs8099917 (T > G), which are located 3 kb
and 8 kb upstream of the IL28B gene, respectively, and rs8103142
(T > C), which is located in exon 2.
As a function of the immunologic aspects of HTLV-1 infections
and the pathophysiology of rheumatic diseases, the present study
investigated for the very first time the association between SNPs
of the IL28B gene and the development of HAA.2. Materials and methods
2.1. Study population
The present study was conducted with 96 HTLV-1-infected indi-
viduals, with 64 being asymptomatic (19 men and 45 women) and
32 (six men and 26 women) exhibiting the signs and symptoms of
rheumatic disease. All patients received care at the Outpatient
Clinic for Infectious Diseases, Tropical Medicine Unit, Federal
University of Pará Universidade Federal do Pará (Ambulatório de
Infectologia do Núcleo de Medicina Tropical da Universidade Fed-
eral do Pará – UFPA). Patient ages varied from 21 to 79 years old.
All patients were assessed by a rheumatologist, who verified the
presence of symptoms meeting all of the diagnostic criteria for
rheumatic disease. Thus, the patients were clinically evaluated as
to the presence of tenosynovitis, joint pain and arthritis in addition
to myalgia and proximal muscle weakness, the latter being
assessed by means of the Mingazzini test. The individuals present-
ing with a predominance of pain and signs of inflammation in large
joints with a mono-, oligo- or polyarticular pattern were selected
for the present study. The control group was composed of 300
HTLV-1 seronegative individuals from both genders (150 menand 150 women) aged 19 to 68 years old without symptoms of
joint disease.2.2. Sample collection
Blood samples (5 mL) were collected in EDTA-coated tubes from
all of the participants. The samples were sent to the Laboratory of
Virology, Institute of Biological Sciences, UFPA, where they were
tested for anti-HTLV-1/2 antibodies via enzyme-linked
immunosorbent assay (ELISA); infection was confirmed via nested
polymerase chain reaction (PCR) as described previously [27].2.3. Ethical issues
The study was approved by the research ethics committee of
João de Barros Barreto University Hospital (process No.
2061/2005) in compliance with Health National Council resolution
196/96, which addresses the guidelines and regulatory norms for
human subjects research.2.4. DNA extraction
Total DNA was extracted from peripheral blood leukocytes
using the phenol–chloroform method. The procedure included cell
lysis, protein precipitation and DNA purification steps, as previ-
ously described [27].2.5. Polymorphism determination
The extracted DNA was subjected to real-time PCR (qPCR) using
a Step One PLUS Sequence Detector (Life Technologies, Foster City,
CA, USA). The assays used for each polymorphism included one
pair of primers and one pair of probes; VIC and FAM labeling
was applied to each allele of the corresponding polymorphisms.
The target sequence of polymorphism rs12979860 was sent to
Applied Biosystems, which designed the following primer and
probe sequences: 50-GCC TGT CGT GTA CTG AAC CA-30 (forward
primer), 50-GCG CGG AGT TGC AAT TCA AC-30 (reverse primer),
50-TGG TTC GCG CTT C-VIC-30 (allele C probe) and 50-FAM-TGG
TTC GTG CTT C-30 (allele T probe). The same was performed in
the case of polymorphism rs8103142, resulting in the following
primer and probe sequences: 50-GCC TCA GGT CCC AGG TC-30 (for-
ward primer), 50-GCC TTT GCT GTC TAG GAA GAG T-30 (reverse pri-
mer), 50-CGG CAC CTG CAG TC VIC-30 (probe) and 50-CGG CAC TTG
CAG TC FAM-30 (probe).
For polymorphism rs8099917, pre-designed assay part number
C_11710096_10 (Life Technologies, Foster City, CA, USA) was used.
A total of 5.0 lL of TaqMan Universal PCR Master Mix [2X],
0.5 lL of TaqMan Assay [20X], 3.5 lL of H2O and 1 lL of DNA
were used in each reaction, with a final reaction volume of 10 lL.
The following parameters were used for the amplification and
detection of alleles: 60 C for 30 s, followed by 95 C for 10 min,
50 cycles at 92 C for 30 s and 60 C for 90 s.2.6. CD4+ and CD8+ T cell count
The blood samples from the individuals diagnosed with HTLV
infection were processed within four hours of collection. The T cell
count was performed via flow cytometry (BD FACSCalibur 4 colors)
using a BD Multitest immunomonitoring kit according to the stan-
dards recommended by the manufacturer (BD Biosciences, San
Jose, CA, USA).
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The proviral load was measured via qPCR using the three-
target-sequence TaqMan system formulated by Life Technologies
(Life Technologies, Foster City, CA, USA) according to a previously
described protocol [28].2.8. Serum cytokines measurement
The serum concentrations of cytokines TNF-a, TNF-b, IFN-c,
IL-6, IL-8 and IL-10 were measured using ELISA (Human
ELISAReady-SET-Go, EBioscience, Inc. California, San Diego, USA).
This method uses specific monoclonal antibodies to detect the
aforementioned cytokines and was performed according to the
manufacturer’s instructions.2.9. Statistical analysis
The allelic and genotypic frequencies were calculated by direct
counting. Comparative analysis of the allelic and genotypic fre-
quencies and the calculation of the Hardy–Weinberg equilibrium
were performed using the chi-square (v2) test. Simple logistic
regression analysis was performed to investigate the association
of the genetic models (dominant and recessive) with the risk of
developing HAA.
The linkage disequilibrium and haplotype analyses were per-
formed using Haploview software v4.2 [29]. The haplotypes were
constructed using the Haploview 4.2 Expectation Maximization
algorithm [29], which provides highly precise estimates of popula-
tion frequencies. D0 confidence interval 0.7–0.98 was considered as
indicative of high linkage disequilibrium.
CD4+ and CD8+ T cells count, proviral load and serum cytokine
levels were submitted to the Shapiro–Wilk test for assessing the
existence of a normal distribution. The variables which were in a
normal distribution were compared using Student’s t-test. In the
absence of normal distribution comparative analyzes were per-
formed using the Mann–Whitney test. In the presence or absence
of normal distribution the correlation analyzes were performed
by Pearson’s and Spearman’s tests, respectively, with two-tailed p
and alpha < 0.05. The tests were performed using BioEstat 5.0
[30] and GraphPad Prism 5.0 [31] software; the significance level
was set to 5% (p < 0.05).Table 1
Allelic and genotypic frequencies of IL28B gene polymorphisms.
Genetic profile Control HTLV-1 v2 p
n (%) n (%)
rs8103142
TT 81 (27.0) 25 (26.3)
TC 147 (49.0) 46 (48.4)
CC 72 (24.0) 24 (25.3) 0.065 0
T 309 (51.5) 96 (50.5)
C 291 (48.5) 94 (49.5) 0.055 0
rs8099917
TT 141 (47.0) 44 (45.8)
TG 132 (44.0) 42 (43.8)
GG 27 (09.0) 10 (10.4) 0.178 0
T 414 (69.0) 130 (67.7)
G 186 (31.0) 62 (32.3) 0.113 0
rs12979860
CC 80 (26.7) 26 (26.8)
CT 150 (50.0) 48 (49.5)
TT 70 (23.3) 23 (23.7) 0.009 0
C 310 (51.7) 100 (51.6)
T 290 (48.3) 94 (48.4) 0.001 0
HTLV-1: Human T lymphotropic virus type 1. HAA: HTLV-1-associated arthropathy.3. Results
3.1. Allelic and genotypic frequencies
The allelic and genotypic frequencies of polymorphisms
rs8103142, rs12979860 and rs8099917 among (symptomatic and
asymptomatic) HTLV carriers and controls are described in Table 1.
Hardy–Weinberg analysis showed that all the populations were at
equilibrium (p > 0.05).
Analysis of polymorphism rs8103142 showed that allele T and
heterozygous genotype TC were the most frequent among the
investigated groups. Genotype TC occurred in 49% of the controls
and 48.4% of the patients, being more prevalent among asymp-
tomatic individuals (52.4%) compared to those with HAA (40.6%).
Analysis of polymorphism rs8099917 showed that homozygous
genotype TT was the most frequent in all of the groups, its fre-
quency varying from 45.3% among the asymptomatic patients to
47% in the control group. Relative to polymorphism rs12979860,
heterozygous genotype CT was the most prevalent in all of the
groups, its frequency varying from 43.8% to 52.3%. Allele C was
the most frequent, varying from 51.7% in the control group to
51.6% among the patients. This high frequency persisted in the
asymptomatic patient group (53.8%), falling to 46.9% among
patients with HAA. None of the differences in the allelic and geno-
typic frequencies was statistically significant, and none of the sug-
gested genetic models were associated with the risk of developing
HAA (Table 2).
Considerable linkage disequilibrium among SNPs rs8103142/
rs12979860 (D0: 0.934; LOD: 30.42; r2: 0.854; confidence interval
D’: 0.86–0.98), rs8103142/rs8099917 (D0: 0.918; LOD: 11.46; r2:
0.405; confidence interval D’: 0.76–0.98) and rs12979860/
rs8099917 (D0: 1.0; LOD: 16.12; r2: 0.491; confidence interval D’:
0.89–1.00) was found between HAA patients and asymptomatic
individuals (Fig. 1A). Imbalance was also found relative to SNPs
rs8103142/rs12979860 (D’: 0.934; LOD: 30.42; r2: 0.854; confi-
dence interval D0: 0.86–0.98), rs8103142/rs8099917 (D0: 0.918;
LOD: 11.46; r2: 0.405; confidence interval D0: 0.76–0.98) and
rs12979860/rs8099917 (D0: 1.0; LOD: 16.12; r2: 0.491; confidence
interval D0: 0.89–1.00) between the non-infected control group and
the HTLV-infected individuals (Fig. 1B). Analysis of asymptomatic
and HAA patients (Fig. 1A) and of non-infected controls and
HTLV-infected patients (Fig. 1B) showed significant linkage dise-
quilibrium (LOD > 2).HAA Asymptomatic v2 p
n (%) n (%)
10 (31.3) 15 (23.8)
13 (40.6) 33 (52.4)
.9681 9 (28.1) 15 (23.8) 1.209 0.5465
33 (51.6) 63 (50.0)
.8802 19 (48.4) 63 (50.0) 2.685 0.1407
15 (46.9) 29 (45.3)
14 (43.7) 28 (43.8)
.9146 3 (09.4) 7 (10.9) 0.061 0.9698
44 (68.7) 86 (67.2)
.8053 20 (31.3) 42 (32.8) 0.048 0.9565
8 (25.0) 18 (27.7)
14 (43.8) 34 (52.3)
.9956 10 (31.2) 13 (20.0) 1.520 0.4677
30 (46.9) 70 (53.8)
.9573 34 (53.1) 60 (46.2) 0.834 0.4468
Table 2
Genetic models and the risk of developing HAA in HTLV-patients.
Genetic model SNP Genotype Frequencies OR 95% CI p valuea
Asymptomatic HAA
n (%) n (%)
rs8103142
Dominant TT 15 (23.8) 10 (31.3) 1
TC + CC 48 (76.2) 22 (68.7) 0.6875 0.27–1.77 0.4376
Recessive TT + TC 48 (76.2) 23 (71.9) 1
CC 15 (23.8) 09 (28.1) 1.2522 0.48–3.28 0.6476
rs8099917
Dominant TT 29 (45.3) 15 (46.9) 1
TG + GG 35 (54.7) 17 (53.1) 0.9390 0.40–2.20 0.8848
Recessive TT + TG 57 (89.1) 29 (90.6) 1
GG 07 (10.9) 03 (09.4) 0.8424 0.20–3.50 0.8134
rs12979860
Dominant CC 18 (27.7) 08 (25.0) 1
CT + TT 47 (72.3) 24 (75.0) 1.1489 0.44–3.02 0.7784
Recessive CC + CT 52 (80.0) 22 (68.7) 1
TT 13 (20.0) 10 (31.3) 1.8182 0.69–4.76 0.2239
HAA: HTLV-1-associated arthropathy.
a Simple logistic regression.
Fig. 1. Pairwise linkage disequilibrium (LD) of the analyzed IL28B gene polymor-
phisms. HAA  Asymptomatics (A) and HTL-positive group  Control group (B). r2
values are presented as percentages. ⁄p < 0.05.
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Haplotypes 1 (TCT), 2 (CTG), 3 (CTT), 4 (CCT), 5 (TCG) and 6 (TTT)
occurred in both controls and HTLV-infected individuals (Table 3),
whereas haplotype 7 (TTG) was found only among HTLV-infected
patients (p = 0.0119), specifically in the subgroup with HAA
(p = 0.0510). Haplotype 4 (CCT) was more frequent among HTLV-
infected individuals compared to the controls (p = 0.0138).3.2. CD4+ and CD8+ T cell count and proviral load
Comparative analysis of the CD4+ T cell count between HAA
patients and the asymptomatic individuals did not reveal any sig-
nificant differences (Fig. 2A), as was the case relative to polymor-
phisms rs8103142, rs8099917 and rs12979860 (data not shown).
No difference was found in the CD8+ T cell count between
patients with HAA and the asymptomatic patients (Fig. 2B).
Nevertheless, when the presence of polymorphism rs8099917
was considered (Fig. 3J), the CD8+ T cell count was higher among
patients with both HAA and genotype TT compared to the asymp-
tomatic patients (p < 0.05). Polymorphisms rs8103142 andrs12979860 were not associated with significant differences (data
not shown).
The proviral load for asymptomatic patients and HAA patients is
depicted in Fig. 2C. No significant difference was found in proviral
load, regardless of the presence of polymorphisms rs8103142 and
rs12979860 (data not shown). However, when the presence of
polymorphism rs8099917 was considered (Fig. 3K), a difference
was found between patients with genotypes TT or TG/GG in the
HAA group (p < 0.05) as well as between the groups of asymp-
tomatic and symptomatic individuals with genotype TT (p < 0.05).3.3. Serum cytokine concentrations
The concentration of TNF-a did not significantly differ between
asymptomatic individuals and HAA patients (Fig. 2D), regardless of
whether the presence of polymorphisms rs8099917, rs8103142
and rs12979860 was considered (data not shown).
The concentration of TNF-b did not significantly differ between
patients with HAA and asymptomatic patients (Fig. 2E), whether
the presence polymorphism rs8099917 was considered (data not
shown). However, when the presence of polymorphism
rs8103142 was considered, the TNF-b levels were higher in
patients with both HAA and genotype TT compared to those with
genotype TC/CC (Fig. 3F; p < 0.05). Considering the presence of
polymorphism rs12979860 (Fig. 3A), the TNF-b levels were higher
in symptomatic patients with genotype CC compared to those with
genotype CT/TT (p < 0.05). No difference was found in this regard in
the group of asymptomatic patients.
IFN-c concentrations were not significantly different between
symptomatic and asymptomatic patients (Fig. 2F), nor were they
different when the presence of polymorphism rs8099917 was con-
sidered (data not shown). However, when the presence of poly-
morphism rs8103142 was taken into account (Fig. 3G), IFN-c
levels were significantly higher among patients with both HAA
and genotype TT (p < 0.05) compared to those with genotype TC/
CC. IFN-c levels were also higher among the symptomatic patients
compared to the asymptomatic patients when carriers of genotype
TT were considered (p < 0.05).
Regarding polymorphism rs12979860 (Fig. 3B), IFN-c levels
were higher among symptomatic patients compared with asymp-
tomatic patients carrying genotype CC (p < 0.05). IFN-c levels were
also higher among patients with both HAA and genotype CC com-
pared to patients with genotype CT/TT (p < 0.05).
Table 3
Frequencies of IL-28B haplotypes among HTLV and control groups.
Haplotypes Control frequencies HTLV-1 frequencies p value Asymptomatic frequencies HAA frequencies p value
#1 (TCT) 0.509 0.483 0.5338 0.492 0.468 0.7638
#2 (CTG) 0.306 0.313 0.8530 0.330 0.281 0.4898
#3 (CTT) 0.176 0.165 0.7497 0.145 0.203 0.3101
#4 (CCT) 0.003 0.021 0.0138 0.033 0.000 0.1488
#5 (TCG) 0.004 0.001 0.4782 0.000 0.001 –
#6 (TTT) 0.002 0.005 0.3837 0.000 0.016 0.1669
#7 (TTG) 0.000 0.011 0.0119 0.000 0.031 0.0510
Notes: The distribution of the seven haplotypes in haplotype block 1. The order is rs8103142, rs12979860, rs8099917. (–) Numerical values do not allow statistical tests to be
performed. HTLV-1: Human T lymphotropic virus type 1. HAA: HTLV-1-associated arthropathy.
Fig. 2. Immune profile of HTLV-infected patients with or without HAA. (A – I) Bar graphs representing the mean and standard deviation of CD4+ (A) and CD8+ (B) T cells count,
proviral load (C) and the concentration of cytokines TNF-a (D), TNF-b (E), IFN-c (F), IL-6 (G), IL-8 (H) and IL-10 (I) in HAA patients or asymptomatic patients. (J – N) Bar graph
representing the mean and standard deviation of the following ratios between serum cytokines: TNF-a/IL-10 (J), TNF-b/IL-10 (K), IFN-c/IL10 (l), IL-6/IL-10 (M) and IL-8/IL-10
(N). ⁄p < 0.05.
K.S.G. de Sá et al. / Cytokine 77 (2016) 79–87 83The IL-8 levels did not significantly differ between asymp-
tomatic patients and patients with HAA (Fig. 2H), whether the
presence of polymorphisms rs8099917 and rs8103142 was consid-
ered (data not shown). However, when polymorphism rs12979860
(Fig. 3D) was considered, the IL-8 levels were lower among symp-
tomatic patients with genotype CC compared to patients with
genotype CT/TT (p < 0.05) and asymptomatic patients (p < 0.05).
IL-6 levels were lower among patients with HAA (p < 0.05;
Fig. 2G). When the presence of polymorphism rs8103142 was con-
sidered, IL-6 levels were higher among asymptomatic patients
with genotypes TC and CC compared to those with genotype TT
(Fig. 3H; p < 0.05). As for polymorphism rs12979860, IL-6 levels
were higher among asymptomatic patients with genotypes CT
and TT (Fig. 3C) compared to patients with HAA (p < 0.05). Similar
results were obtained by performing intragroup analyses compar-
ing asymptomatic patients with genotype CC (p < 0.05).The levels of IL-10 were higher among patients with HAA com-
pared to asymptomatic individuals (Fig. 2I; p < 0.05). When the
presence of polymorphism rs8099917 was considered (Fig. 3M),
IL-10 levels were higher among symptomatic patients with geno-
types TG and GG (p < 0.05) compared to asymptomatic patients.
When considering polymorphisms rs8103142 (Fig. 3I; p < 0.05)
and rs12979860 (Fig. 3E; p < 0.05), IL-10 levels were higher among
patients with both HAA and genotypes TC or CC and CT or TT,
respectively, compared to asymptomatic patients. Similar results
were found among HAA patients with polymorphism rs8103142
genotypes TC and CC (p < 0.05).
3.4. Cytokine balance comparison
A comparison of the serum cytokine balance between HAA
patients and asymptomatic individuals (Fig. 2J–N) revealed signif-
Fig. 3. Association of IL28B gene polymorphisms and HAA. (A – E) Bar graphs representing the mean and standard deviation of the concentration of cytokines TNF-b (A), IFN-c
(B), IL-6 (C), IL-8 (D) and IL-10 (E) per rs12979860 polymorphism genotype. (F – I) Bar graphs representing the mean and standard deviation of the concentration of cytokines
TNF-b (F), IFN-c (G), IL-6 (H) and IL-10 (I) per rs8103142 polymorphism genotype. (J – M) Bar graphs representing the mean and standard deviation of CD8+ (J) T cell count,
proviral load (K) and the concentration of cytokines IL-6 (L) and IL-10 (I) per rs8099917 polymorphism genotype. ⁄p < 0.05.
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(Fig. 2K; p < 0.05) and IFN-c/IL-10 ratios (Fig. 2L; p < 0.05), with
lower values observed in symptomatic patients. The IL-6/IL-10
(Fig. 2M) and IL-8/IL-10 ratios (Fig. 2N) did not exhibit significant
differences.3.5. Correlation of CD4+/CD8+ T cell count and proviral load with
cytokine concentrations
Correlation analyses revealed significant differences between
TNF-a levels and CD4+ (Fig. 4A; p = 0.0212; r = 0.3995) and CD8+
T cell counts (Fig. 4B; p = 0.0484; r = 0.3461). Similar results were
obtained with respect to the correlation between IFN-c levels
(Fig. 4C; p = 0.0549; r = 0.3322) and proviral load among asymp-
tomatic patients. Analyzing the correlation of cytokines TNF-b,
IL-6, IL-8 and IL-10 with proviral load and CD4+ and CD8+ T cell
count between asymptomatic and HAA patients did not reveal
any significant differences (data not shown).4. Discussion
Few studies have sought to explain the development of HAA.
Yakova et al. (2005) found that the HTLV proviral load was higherin a group of 12 patients with rheumatoid arthritis compared with
asymptomatic infected controls and similar to that exhibited by
patients with HAM/TSP. These findings indicate that just as in
HAM/TSP, viral replication also plays a relevant role in the develop-
ment of HAA [32]. Our results disagree with those of Yakova et al.
(2005), as the proviral load in the peripheral blood of the 32 indi-
viduals with HAA was similar to that detected in asymptomatic
patients. Our results thus suggest that the mechanism underlying
HAA might differ from the one attributed to HAM/TSP. Our results
also did not demonstrate any difference in CD4+ and CD8+ T cell
counts between symptomatic and asymptomatic patients, which
suggests that the number of these cells is not a limiting factor for
the development of HAA.
One explanation put forward to account for the development of
HAA asserts that HTLV displays tropism for synovial cells [13],
which, once infected, are stimulated to proliferate by viral protein
Tax [14]. The Tax protein might further activate transcription fac-
tors such as Nf-jB, consequently stimulating the production of
several proinflammatory cytokines, including TNF-a, IFN-c, IL-6
and TNF-b [14,33,34], resulting in cartilage destruction and joint
erosion. Our results did not indicate any significant difference in
serum TNF-a, TNF-b, IFN-c and IL-8 concentrations between
patients with HAA and asymptomatic individuals. However, IL-10
levels were higher and IL-6 levels were lower among the former
Fig. 4. Dispersion of the individual cytokine values versus CD4+ (A) and CD8+ (B) T cells count and proviral load (C); the p and r (Pearson) values and the trend line are
represented in the graph. ⁄p < 0.05.
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antirheumatic drugs, since it has been reported that these drugs
decrease IL-6 dosages [35], but without effect on the dosages of
IL-10 [36,37]. Furthermore, we measured the serum levels of both
cytokines, which might differ from their synovial concentrations,
which characterize local inflammatory reactions. These results
are consistent with previous report that described high levels of
IL-10 among patients with arthritis [37].
Such high IL-10 and low IL-6 levels in the peripheral blood
might be indicative of good prognosis, as high IL-6 expression
has been associated with the occurrence of HAA [38], the reason
being that IL-6 is associated with the stimulation of bone resorp-
tion [39]. However, high IL-10 levels were also found in patients
with ATLL [40], which might be because the viral Tax protein is
able to stimulate IL-10 production [41]. Depending on the activa-
tion status of CD8+ T cells, IL-10 might stimulate their proliferation
[42] and even increase their intracellular expression of the Th1
cytokine profile [43]. When such cytokines are secreted in the syn-
ovia, they might play a role in the development of joint disease;
this hypothesis still requires further confirmatory studies.
The balance between proinflammatory and regulatory cytoki-
nes affords a better demonstration of the mechanisms involved
in the immune response of patients. In the present study, the aver-
age TNF-a/IL-10, TNF-b/IL-10 and IFN-c/IL-10 ratios were lower
among HAA patients compared with asymptomatic patients, which
might be related to the use of antirheumatic drugs, as mentioned
above.
Correlation analysis showed that in the group of asymptomatic
patients, TNF-a levels increased in parallel with the number of
CD4+ and CD8+ T cells. Similarly, a positive correlation was also
found between INF-c levels and the proviral load, as described pre-
viously [44]. However, no such correlations were detected relative
to patients with HAA, indicating that these phenomena are not
required for HAA to occur. That same lack of correlation was also
found by other authors relative to HAM/TSP [44,45].
IL-28 exhibits antiviral and immunomodulatory activity; it is
secreted by macrophages and plasmacytoid dendritic cells – pDCs
[23–25,46,47] and has been shown to increase the number of
CD8+ T cells in the peripheral blood of mice and monkeys and to
reduce the number of regulatory T cells in mice [26,48].
Studies have shown that polymorphisms of the IL28 gene are
associated with the progression of HTLV-1 infection [49] and that
these polymorphisms play an important role in the development
and control of HAM/TSP pathogenesis [50,51]. In the present study,
the allelic and genotypic frequencies of the investigated polymor-
phisms and the analyzed genetic models suggest that these poly-
morphisms by themselves do not determine the susceptibility to
infection and the development of HAA. Our results further indicate
that the number of CD4+ T cells in the peripheral blood is not asso-
ciated with the genetic variability observed in the IL28 gene.Analyzing polymorphism rs8099917 revealed that the proviral
load and CD8+ T cell count were higher in patients with HAA and
genotype TT compared with asymptomatic patients. These findings
suggest that genotype TT is associated with poor prognosis of HAA,
as the increase in the number of CD8+ T cells was associated with
greater proviral load; these phenomena might make such patients
a high-risk group for HAM/TSP. Studies have shown that genotype
TT is associated with lower IL-28 expression, with consequently
lower stimulation of the interferon stimulated genes – ISGs
[52,53]. However, in patients treated with IFN-a, genotype TT is
associated with increased stimulation of ISGs, resulting in better
responses to treatment [54], which makes it protective against
infection with the hepatitis C virus – HCV [55–58]. Patients with
HAA are often treated with antirheumatic drugs that suppress
the immune system, which in fact might be a determinant for
the progression of infection in patients with genotype TT and
low ISG expression.
SNP rs8099917 allele G has been associated with high ISG
expression [53], which accounts for the high IL-6 levels found
among the asymptomatic patients. Nevertheless, this cytokine pro-
file might make these patients a high-risk group for HAA [40].
Recently, it was demonstrated the genotype GG (rs8099917) asso-
ciated with HAM/TSP [51].
Patients with HAA and the wild-type genotype (CC) of polymor-
phism rs12979860 exhibited high TNF-b and IFN-c production,
which might increase the synovial expression of major histocom-
patibility complex (MHC) molecules and thus contribute to the
pathogenesis of infection [14,59] in addition to stimulating bone
resorption and inhibiting the synthesis of collagen [60]. Polymor-
phism rs12979860 was also associated with reduced IL-8 levels
in the peripheral blood, which may be a protective factor against
the development of HAA, as IL-8 is related to the development of
rheumatoid arthritis [61].
Patients with HAA and genotype CT/TT (rs12979860) exhibited
reduced TNF-b and IFN-c production, which might be related to
the possible suppression of ISG expression [55]. Several authors
characterized genotype CC as having a good immune response
[62] and genotype CT/TT as having a suppressed immune response
[62–64], which might account for the results of the present study.
However, such good immune responses are associated with the
increased production of proinflammatory cytokines, which is coun-
terbalanced by the aforementioned reduction in IL-8 levels. As a
result, this polymorphismmight be associated with poor prognosis
in the development of HAA. The differences in IL-6 and IL-10 levels
might be explained by the large linkage imbalance between poly-
morphisms rs8099917 and rs12979860 [65,66]. As such, the differ-
ence is attributed to polymorphism s12979860 and the use of
antirheumatic drugs by those patients. Our results agree with San-
abani et al. (2012), showing a lack of correlation between the
rs12979860 polymorphism and HTLV-1 proviral load [67].
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cell count, proviral load, and TNF-a and IL-8 levels suggests that
this polymorphism has no relationship with these markers. Never-
theless, patients with HAA and the wild-type genotype (TT) of SNP
rs8103142 exhibited higher TNF-b and IFN-c levels, which might
be an aggravating factor for the development of the disease. High
TNF-b levels have been shown to stimulate the bone resorption
and inhibit collagen synthesis in vitro [60], while IFN-c stimulates
the expression of MHCmolecules, leading to increased antigen pre-
sentation in the synovial membrane [14,59]. These differences,
however, might be related to the large linkage imbalance between
polymorphisms rs8103142 and rs12979860 [65]. Those patients
with HAA and genotypes TC and TT exhibited higher IL-10 levels
compared with asymptomatic individuals, which might have a
protective effect by regulating the high TNF-b and IFN-c levels of
the wild-type genotype. Nevertheless, asymptomatic individuals
with the same genotype exhibited higher IL-6 levels.
Analysis of the set of haplotypes constituted by the investigated
polymorphisms showed that haplotype CTT might be associated
with susceptibility to HTLV infection. Studies have suggested that
polymorphism rs8103142 might induce a less effective, albeit
more sustained, antiviral response [66]. In addition, alleles C
(rs12979860) and T (rs8099917) have been associated with good
immune responses [56,67,68] and reduced Il-28 and ISG expres-
sion [52,53], respectively. In combination, these characteristics
might influence the susceptibility to HTLV infection and the high
frequency of this haplotype among asymptomatic patients.
Haplotype TTG might be associated with the progression to
HAA, as alleles T (rs12979860) and G (rs8099917) are related to
aberrant induction of immune system pathways [62] and increased
ISG expression [53], respectively, which combined might influence
the progression of infection.
5. Conclusion
We conclude that the IL28B gene and its polymorphisms might
play an important role in the development of HAA and influence
the progression of disease. The reason is that genotype TT
(rs8099917) seems to behave as a risk factor for having high cyto-
toxic T cell counts and proviral load levels, while the presence of
genotypes TT (rs8103142) and CC (rs12979860) seems to be an
aggravating factor that is associated with elevated serum TNF-b
and IFN-c levels. In contrast, genotypes TC and CC of polymor-
phism rs8103142 most likely behave as protective factors, as they
are associated with high IL-10 levels. In addition, the results sug-
gest that haplotype CCT is associated with susceptibility to HLTV
infection and haplotype TTG with progression to HAA.
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